IL1B and acute respiratory distress syndrome: In contrast, the 10 mg/kg BMSCs‐Exos treatment group exhibited significant reductions in TNF‐α and IL‐1β, along with a notable increase in IL‐10 (p < 0.01 or p < 0.05 vs. the ALI group) (Figure 5E).